Sodium-Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes.
SGLT2 inhibitors
canagliflozin
cardiovascular outcome trials
diabetes
empagliflozin
heart failure
Journal
Cardiac failure review
ISSN: 2057-7540
Titre abrégé: Card Fail Rev
Pays: England
ID NLM: 101696210
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
03
07
2019
accepted:
21
09
2019
entrez:
27
11
2019
pubmed:
27
11
2019
medline:
27
11
2019
Statut:
epublish
Résumé
Diabetes and heart failure (HF) are closely linked, with one causing a worse prognosis in the other. The majority of anti-hyperglycaemic agents primarily reduce risk of ischaemic microvascular events without targeting the mechanisms involved for diabetes cardiomyopathy and HF. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a novel class of glucose-lowering agents that have consistently reduced HF hospitalisations, unlike other agents. The authors discuss the current evidence and highlight possible future directions for the role of SGLT2 inhibitors in HF prevention.
Identifiants
pubmed: 31768274
doi: 10.15420/cfr.2019.06.R1
pmc: PMC6848945
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
169-172Informations de copyright
Copyright © 2019, Radcliffe Cardiology.
Déclaration de conflit d'intérêts
Disclosure: JB has received research support from the NIH, Patient-Centered Outcomes Research Institute and the EU. He serves as a consultant for Abbott, Adrenomed, Amgen, Array, Astra Zeneca, Bayer, Boehringer Ingelheim, BMS, CVRx, Innolife, Janssen, LinaNova, Luitpold, Medtronic, Merck, Novartis, NovoNordisk, Relypsa, Roche, Sanofi, V-Wave and Vifor. MSK has no has no conflicts of interest to declare.
Références
JACC Heart Fail. 2018 Oct;6(10):823-830
pubmed: 30196071
J Am Coll Cardiol. 2018 Mar 27;71(12):1379-1390
pubmed: 29534825
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Eur J Prev Cardiol. 2019 Apr 9;:2047487319841936
pubmed: 30966822
J Am Coll Cardiol. 2012 Oct 16;60(16):1455-69
pubmed: 22999723
Am J Med. 2017 Jun;130(6S):S30-S39
pubmed: 28526184
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-854
pubmed: 31495651
JACC Heart Fail. 2015 Feb;3(2):136-45
pubmed: 25660838
J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639
pubmed: 29540325
JACC Heart Fail. 2018 Oct;6(10):813-822
pubmed: 30098964
Circ Heart Fail. 2018 Jun;11(6):e004646
pubmed: 29793934
Eur J Prev Cardiol. 2019 Oct;26(15):1680-1682
pubmed: 30755019
BMJ. 2018 Feb 6;360:k119
pubmed: 29437648
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
N Engl J Med. 2013 Oct 3;369(14):1317-26
pubmed: 23992601
Eur Heart J. 2010 Apr;31(7):824-31
pubmed: 20118174
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Circulation. 2016 Sep 6;134(10):752-72
pubmed: 27470878
Diabetologia. 2018 Dec;61(12):2461-2498
pubmed: 30288571
J Diabetes. 2019 Jul;11(7):601-604
pubmed: 31044514
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
Eur Heart J. 2018 Feb 1;39(5):363-370
pubmed: 29020355
N Engl J Med. 2018 Aug 16;379(7):633-644
pubmed: 30110583
Diabetes Care. 2017 Dec;40(12):1763-1770
pubmed: 28986504
Diabetes Care. 2018 Jan;41(Suppl 1):S73-S85
pubmed: 29222379
Circulation. 2014 Feb 4;129(5):587-97
pubmed: 24334175
J Am Coll Cardiol. 2018 Jun 5;71(22):2497-2506
pubmed: 29852973
Metabolism. 2017 Dec;77:65-72
pubmed: 29132539
Eur Heart J. 2016 May 14;37(19):1526-34
pubmed: 26819227